Although there is heterogeneity in PSMA expression and tracer uptake, a subset of patients with advanced salivary gland cancer, glioblastoma, thyroid cancer, hepatocellular carcinoma, and clear cell renal carcinoma show sufficient PSMA PET/CT tracer uptake in the tumor. This evidence concerns the gene FOLH1 and salivary gland cancer.